We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Harvoni

News List

Brazilian court strips Gilead of its patent for Hepatitis C drug Sovaldi pharmaceutical-technology
September 30, 2018
A judge from the 21st Federalist Court of Brasilia has ruled to invalidate US biopharma company Gilead’s exclusivity patent for Sovaldi (sofosbuvir), which is indicated for Hepatitis C.
Gilead to release generic versions of hep C meds over a decade before patent expiry pharmafile
September 29, 2018
Gilead has announced its intention to undercut itself by releasing generic versions of its blockbuster drugs for the treatment of hepatitis C, Epclusa (sofosbuvir/velpatasvir)...
FDA approves new indications for Harvoni and Sovaldi cphi-online
April 11, 2017
First HCV direct-acting antivirals approved for use in adolescents.